BACKGROUND: Randomized trials of advanced non-small cell lung cancer (NSCLC) have
demonstrated the activity of docetaxel in second-line and erlotinib in the third-line setting …

BACKGROUND: Both docetaxel and erlotinib improve overall survival over best supportive
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …

Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

Abstract Purpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—
KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic non …

Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …

LBA7509 Background: This phase III study (V-15–32) compared gefitinib vs docetaxel on
overall survival (OS) in Japanese patients (pts) with pretreated advanced NSCLC. Methods …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …